10 modules · educational use only, not medical advice.
Module 1 · Cardio-oncology
GLP-1–Based Therapies in Cardio-Oncology
Where GLP-1 biology meets survivorship: cardiometabolic risk reduction across the cancer journey, the muscle guardrail, and a prescribing-to-prevention pathway.
Module 2 · Full field guide
GLP-1 Receptor Agonist Therapy: The Complete Briefing
Eleven themes from initiation through emerging evidence — titration ladders, tolerability, switching, lean mass, cardiovascular benefit, regain, virtual care, coverage, and communication.
Module 3 · Evidence · cost · coverage
Obesity, Cardiometabolic Health & GLP-1 Therapies
How the agents work, SURMOUNT-5 head-to-head weight loss, SELECT cardiovascular benefit, safety, cost, coverage, and adherence.
Module 4 · Safety
Managing Adverse Effects & Safety Considerations
The gastrointestinal signal that dominates, the rare-but-serious risks, why stepwise escalation limits harm, and what to monitor.
Module 5 · Case-based
Avoiding Common GLP-1 Prescribing Mistakes
Six errors that drive denials and harm — indication mismatch, fast titration, missed contraindications, interactions, compounded use, and thin documentation.
Module 6 · Muscle
Preserving Lean Mass During GLP-1 Weight Loss
Not all weight lost should be muscle. Why lean mass matters for survivors, and the four levers that protect it during rapid weight loss.
Module 7 · The exit plan
Weight Regain After GLP-1 Discontinuation
Stopping therapy tends to reverse the gains. The regain trajectory, who is at highest risk, and how to plan the off-ramp before it happens.
Module 8 · Delivery
Virtual Care Models for Obesity & Cardiometabolic Disease
Convenience is real; so are the gaps. What good telehealth GLP-1 care looks like, and the guardrails that separate it from a prescription pipeline.
Module 9 · Communication
Patient Communication & Shared Decision-Making
The SHARE approach, the Ottawa framework, decision aids, teach-back, and how a documented shared decision supports medical necessity.
Module 10 · Myths
GLP-1 Receptor Agonists: Myths, Misconceptions & Media Headlines
What a GLP-1 actually is, four brands and two molecules, the myths worth retiring, and the difference between an exciting signal and an oversold headline.
Educational information only. It does not replace advice from your oncology or primary care team, and no treatment decision should be made from these modules alone.